Annotation Detail

Information
Associated Genes
CD274
Associated Variants
CD274 EXPRESSION
CD274 EXPRESSION
Associated Disease
cancer
Source Database
CIViC Evidence
Description
A meta analysis of 60 research studies involving 10,310 solid tumors indicated that CD274 over expression results in poor overall survival (HR = 1.58, P <.001) and poor disease free/progression free survival (DFS/PFS) (HR = 1.72, P =0 .001). When split into sub groups by cancer type overall survival was poor for breast (HR = 1.98, P =0 .014), urothelial (HR = 2.24, P <0.001), renal (HR = 3.30, P <0.001), and gastric cancers (HR = 1.56, P =0 .040). DFS/PFS was poor in patients with hepatocellular carcinoma (HR = 1.72, P = 0.003), melanoma (HR = 3.39, P <0.001), and renal carcinoma, (HR = 5.04, P <0.001).
Variant Origin
N/A
Variant Origin
N/A
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/5507
Gene URL
https://civic.genome.wustl.edu/links/genes/11335
Variant URL
https://civic.genome.wustl.edu/links/variants/276
Rating
4
Evidence Type
Prognostic
Disease
Cancer
Evidence Direction
Supports
Evidence Level
B
Clinical Significance
Poor Outcome
Pubmed
28471952
Drugs